For Physicians
AVEO is conducting ongoing clinical trials investigating tivozanib as a single agent targeted therapy in patients with renal cell carcinoma (RCC) and in combination with other targeted therapies or chemotherapy regimens in patients with RCC, breast, colorectal cancers and other tumors.
We welcome interest from physicians and clinical oncologists in learning more about tivozanib and/or becoming involved in the tivozanib clinical program. If you would like to request additional information on ongoing tivozanib clinical trials, please contact AVEO Medical Affairs at medicalaffairs@aveopharma.com or by phone at (617) 299-5800 (option 1).
If you would like to submit an IST proposal, please download and complete the form below, and submit via email to AVEO Medical Affairs at medicalaffairs@aveopharma.com.